Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, Hoppe-Seyler-Str 3, D-72076 Tübingen, Germany.
J Neurol Neurosurg Psychiatry. 2010 May;81(5):536-8. doi: 10.1136/jnnp.2009.175752. Epub 2010 Feb 22.
Insulin-like growth factor 1 (IGF-1) provides protection against loss of dopaminergic neurons in animal models of Parkinson's disease (PD). The aim of this study was to measure serum IGF-1 in patients with PD and assess its correlation with the clinical presentation.
Serum IGF-1 and growth hormone (GH) levels were measured in 12 patients with idiopathic PD and 12 matched healthy controls, three times over a period of 6 months after overnight fasting. Based on the results, serum IGF-1 was measured in six additional, yet untreated, PD patients.
IGF-1 values were stable over the whole period (r=0.83-0.93) in patients and controls. IGF-1 was significantly higher in treated PD patients than in controls at all time points (all p<0.001). There were no significant differences in serum GH levels between patients and controls. Receiver operating characteristics showed a cut-off at 114 ng/ml for differentiation of treated patients and controls (area under the curve=0.90). In the patient group, higher serum IGF-1 levels were correlated with shorter disease duration (r=-0.56, p=0.001). In the healthy control group, higher IGF-1 was correlated with slightly impaired motor performance, as measured by the Unified Parkinson's Disease Rating Scale motor score (r=0.46, p=0.005). In the untreated patient group, serum IGF-1 levels were significantly higher than in healthy controls (p<0.001). Applying the cut-off value of 114 ng/ml, all untreated patients were correctly classified as PD patients.
Increased IGF-1 might be an interesting serum marker for early PD and potentially for subclinical dopaminergic dysfunction.
胰岛素样生长因子 1（IGF-1）可提供对帕金森病（PD）动物模型中多巴胺能神经元丢失的保护作用。本研究旨在测量 PD 患者的血清 IGF-1 并评估其与临床表现的相关性。
在 12 名特发性 PD 患者和 12 名匹配的健康对照者中，测量了空腹过夜后 6 个月内的血清 IGF-1 和生长激素（GH）水平。基于这些结果，在另外 6 名未经治疗的 PD 患者中测量了血清 IGF-1。
在患者和对照组中，IGF-1 值在整个期间均保持稳定（r=0.83-0.93）。在所有时间点，治疗后的 PD 患者的 IGF-1 值均明显高于对照组（均 p<0.001）。患者和对照组之间的血清 GH 水平无显着差异。接收者操作特征显示，用于区分治疗患者和对照组的截止值为 114ng/ml（曲线下面积=0.90）。在患者组中，较高的血清 IGF-1 水平与较短的病程相关（r=-0.56，p=0.001）。在健康对照组中，较高的 IGF-1 与运动表现略有受损相关，这通过统一帕金森病评定量表运动评分来测量（r=0.46，p=0.005）。在未经治疗的患者组中，血清 IGF-1 水平明显高于健康对照组（p<0.001）。应用 114ng/ml 的截止值，所有未经治疗的患者均正确分类为 PD 患者。
升高的 IGF-1 可能是早期 PD 及潜在亚临床多巴胺能功能障碍的有趣血清标志物。
